While the rules are clear on what needs to be done to comply with pay vs. performance disclosure, there are unique challenges for biotech and pharma.

Providing an excise tax gross-up is sensitive for boards, given its poor reputation. Here is data providing a clear picture of the practice.

A siloed approach to executive pay, business strategy, and leadership development may hinder long-term value creation.

Given the new pay versus performance rules, drafting this year’s CD&A will be an especially heavy lift. Here’s how to get started now.

After 13 years and much debate, the SEC has finalized its guidance for one of the most complex executive compensation disclosures required under the Dodd-Frank Act.

A preview of the trends beginning to emerge ahead of the 2023 pay cycle to help compensation committee members prepare for the next round of pay-setting discussions.

The seniors housing industry has been particularly hard-hit since 2020; here are ideas on rewarding and retaining difference-making talent.

Unlike an earlier proposal, the current Act does not include legislation directly impacting executive compensation, although there may be some derivative impact.

When considering staffing reductions, a fair and empathetic compensation program is imperative in the tight-knit biotech and pharma industries.

Leadership transition is an ongoing process. Here are four guiding points for boards and CEOs that former Pearl Meyer Chairman David Swinford suggested considering.

Data and context on the relationship between historically premium pay for the audit committee chair compared to other committee chairs.

For biotech, the retention value of options is currently in jeopardy. Here are several key points to weigh if your company is considering strong action.